Recruiting Clinical Trials

Tumor-Infiltrating Lymphocytes and Low-Dose Interleukin-2 Therapy Following Cyclophosphamide and Fludarabine in Patients With Pleural Mesothelioma

By April 24, 2017 No Comments

Condition

Pleural Mesothelioma

Estimated Enrollment: 10

Age Group: 18 Years and older   (Adult, Senior)

Gender: All

Study Type: Interventional

Study Design Allocation: Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment

Study ID Numbers: TILs-003-Meso

Study First Received: April 8, 2015

Last Updated: May 31, 2016

Estimated Primary Completion Date: June 2025

 

Primary Outcome Measures:

Total number of adverse events for each event reported and the severity and attribution to study therapy of each event|Percentage of patients with a clinical response to the study treatment

Sponsors and Collaborators:

University Health Network, Toronto

Website Link: https://ClinicalTrials.gov/show/NCT02414945

Leave a Reply

Call Now